148 related articles for article (PubMed ID: 38206922)
1. Curative intent therapy for DLBCL in the elderly.
Tucci A; Masina L; Luminari S
Leuk Lymphoma; 2024 May; 65(5):560-569. PubMed ID: 38206922
[TBL] [Abstract][Full Text] [Related]
2. Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly.
Khan Y; Brem EA
Curr Hematol Malig Rep; 2019 Aug; 14(4):228-238. PubMed ID: 31228094
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
Di M; Huntington SF; Olszewski AJ
Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
[TBL] [Abstract][Full Text] [Related]
4. Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.
Chiappella A; Castellino A; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Apr; 10(4):289-297. PubMed ID: 28290728
[TBL] [Abstract][Full Text] [Related]
5. Analysis of elderly patients with diffuse large B-cell lymphoma: aggressive therapy is a reasonable approach for 'unfit' patients classified by comprehensive geriatric assessment.
Yoshida M; Nakao T; Horiuchi M; Ueda H; Hagihara K; Kanashima H; Inoue T; Sakamoto E; Hirai M; Koh H; Nakane T; Hino M; Yamane T
Eur J Haematol; 2016 Apr; 96(4):409-16. PubMed ID: 26084899
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL).
Tucci A; Martelli M; Rigacci L; Riccomagno P; Cabras MG; Salvi F; Stelitano C; Fabbri A; Storti S; Fogazzi S; Mancuso S; Brugiatelli M; Fama A; Paesano P; Puccini B; Bottelli C; Dalceggio D; Bertagna F; Rossi G; Spina M;
Leuk Lymphoma; 2015 Apr; 56(4):921-6. PubMed ID: 25110825
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Geriatric Assessment (CGA): A Simple Tool for Guiding the Treatment of Older Adults with Diffuse Large B-Cell Lymphoma in China.
Bai JF; Han HX; Feng R; Li JT; Wang T; Zhang CL; Liu H
Oncologist; 2020 Aug; 25(8):e1202-e1208. PubMed ID: 32436258
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.
Yhim HY; Park Y; Kim JA; Shin HJ; Do YR; Moon JH; Kim MK; Lee WS; Kim DS; Lee MW; Choi YS; Jeong SH; Kim KH; Kim J; Lee CH; Song GY; Yang DH; Kwak JY
Korean J Intern Med; 2024 May; 39(3):501-512. PubMed ID: 38287501
[TBL] [Abstract][Full Text] [Related]
10. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy.
Tucci A; Ferrari S; Bottelli C; Borlenghi E; Drera M; Rossi G
Cancer; 2009 Oct; 115(19):4547-53. PubMed ID: 19562776
[TBL] [Abstract][Full Text] [Related]
12. Curing diffuse large B-cell lymphomas in elderly patients.
Moccia AA; Thieblemont C
Eur J Intern Med; 2018 Dec; 58():14-21. PubMed ID: 30472108
[TBL] [Abstract][Full Text] [Related]
13. Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches.
Allen P
Curr Oncol Rep; 2020 Aug; 22(11):114. PubMed ID: 32827063
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice.
Santambrogio E; Novo M; Rota-Scalabrini D; Vitolo U
Expert Rev Hematol; 2020 Aug; 13(8):851-869. PubMed ID: 32741225
[TBL] [Abstract][Full Text] [Related]
15. Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B-cell lymphoma on survival: A systematic review.
Briand M; Gerard S; Gauthier M; Garric M; Steinmeyer Z; Balardy L
Eur J Haematol; 2022 Jan; 108(1):3-17. PubMed ID: 34496073
[TBL] [Abstract][Full Text] [Related]
16. Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era.
Hasselblom S; Stenson M; Werlenius O; Sender M; Lewerin C; Hansson U; Nilsson-Ehle H; Andersson PO
Leuk Lymphoma; 2012 Mar; 53(3):394-9. PubMed ID: 21864039
[TBL] [Abstract][Full Text] [Related]
17. Clinical approach to diffuse large B cell lymphoma.
Caimi PF; Hill BT; Hsi ED; Smith MR
Blood Rev; 2016 Nov; 30(6):477-491. PubMed ID: 27596109
[TBL] [Abstract][Full Text] [Related]
18. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary.
Morrison VA; Hamlin P; Soubeyran P; Stauder R; Wadhwa P; Aapro M; Lichtman SM
Ann Oncol; 2015 Jun; 26(6):1058-1068. PubMed ID: 25635006
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Jung YH; Woo IS; Han CW
Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
